LEIDEN, Netherlands & MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Ncardia and Cellistic proceed to construct their management groups by recruiting Gustavo Mahler as Chief Govt Officer. Gustavo was most lately a Enterprise Accomplice with DYNAMK Capital the place he invested in main life sciences instruments, applied sciences, and providers. Previous to this position Gustavo spent ten years main and rising CMC Biologics (now AGC Biologics) leading to CMC’s sale to Asahi Glass Company for €520 million which created AGC Biologics. Gustavo additionally held international management positions at Bayer Healthcare.
Gustavo holds a Ph.D. in Biochemistry from the College of Buenos Aires and an MBA from the College of Madrid and has attended MIT Sloan College of Administration Govt Training Programs in Management & Administration.
As a part of the administration crew adjustments, Stefan Braam, the founding father of Ncardia and Cellistic, will transfer into the position of President and Chief Technical Officer the place he’ll oversee the group’s technical issues, together with investments in distinctive turn-key immuno-oncology iPSC-based cell remedy platforms.
“We’re thrilled with the continued progress and enlargement of Ncardia and Cellistic,” stated Geoff Glass, Chairman of Ncardia and Cellistic. “Our potential to draw somebody of Gustavo’s caliber to steer the group is a testomony to distinctive alternative to affect superior therapies in a profound manner. Stefan transferring to a task the place his distinctive iPSC experience could be maximized, whereas partnering with Gustavo, who’s so skilled at scaling technical companies into GMP, is a potent mixture.”
“I’m excited to hitch Ncardia and Cellistic, leaders in iPSC house.” Gustavo Mahler, Ncardia and Cellistic CEO, stated, “Our focus might be to speed up the commercialization of latest purposes for discovery and therapeutic growth that ought to remodel the drug growth and cell remedy panorama.”
Stefan Braam, Ncardia President and CTO, stated, “Gustavo’s expertise and experience in main the expansion of corporations like ours each as a CEO and as an investor will allow our maturation and evolution within the coming years, bringing artistic, skilled management to our strategic progress plans.”
Launched in April 2022 as a subsidiary of Ncardia, Cellistic™ makes a speciality of course of growth and manufacture of cell therapies based mostly on human induced pluripotent stem cell (iPSC) know-how. Its focus and experience in iPSC reprogramming, differentiation, and enlargement protocol growth positions the enterprise to be the accomplice of alternative for revolutionary cell remedy builders to commercialize novel superior therapies. Leveraging greater than a decade of Ncardia’s scientific and technical information and expertise, Cellistic possesses distinctive capabilities for the design and optimization of proprietary manufacturing platforms for iPSC- based mostly cells that ship high quality merchandise at scale. For extra data, go to www.cellistic.com.
Ncardia is a human iPSC know-how firm that operates worldwide with services, places of work, and workers all through Europe and North America. Ncardia is constructed on the assumption that stem cell know-how will assist convey higher therapies to sufferers quicker. The corporate’s aim is to allow biopharmaceutical corporations in drug discovery to speed up their growth processes via the combination of human iPSC applied sciences. For extra data, go to www.ncardia.com.